Fusion Antibodies, Eurofins focus on preclinical drug discovery research

UK-based contract research organization Fusion Antibodies has entered into a commercial collaboration with Eurofins, a leading supplier of products and services to the drug discovery industry. The collaboration between Fusion Antibodies and Eurofins Discovery will last for an initial two-year period and is a commitment to provide worldclass scientific expertise, next-generation technology, and guidance to accelerate the delivery of the best possible antibody against a broad range of targets and therapeutic areas into the clinic. Under the agreement, Fusion Antibodies will provide comprehensive preclinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that together they can provide a complete workflow solution for busy researchers. This includes Fusion Antibodies services for antibody generation, characterisation, sequencing, engineering and expression, and Eurofins Discovery’s in vivo and in vitro services, such as efficacy models, bioanalytical services, biomarker development, phenotypic assays and safety assessment.